1032
PROTEOMIC BIOMARKER PROFILING OF AMPULLARY ADENOCARCINOMA (AMPAC) WITHIN THE LANDSCAPE OF PERIAMPULLARY CARCINOMAS TO GUIDE CLINICAL DECISION-MAKING
Date
May 21, 2024
Tracks
Related Products
Hepatobiliary and Pancreatic Diseases
SOCIETY: SSAT
AGGRESSIVE MANAGEMENT OF ELDERLY PATIENTS WITH NON-METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
IMPACT OF LIVER CIRRHOSIS ON SURGICAL COMPLICATIONS, TIME TO RECURRENCE, AND OVERALL SURVIVAL FOLLOWING RESECTION OF PANCREATIC DUCTAL ADENOCARCINOMA: A PROPENSITY-MATCHED STUDY
Management of patients with margin negative, T1-T3, N0 (stage IB–IIIA), resected gallbladder cancer (GBC) remains poorly defined. Current guidelines consider observation, chemotherapy (CT), and chemoradiation (CRT) as options…
IMPLICATIONS OF METASTASIS TO THE COMMON HEPATIC ARTERY NODE IN PANCREATIC ADENOCARCINOMA (PDAC): AN ANALYSIS OF A PROSPECTIVE CONTEMPORARY SERIES
Management of patients with margin negative, T1-T3, N0 (stage IB–IIIA), resected gallbladder cancer (GBC) remains poorly defined. Current guidelines consider observation, chemotherapy (CT), and chemoradiation (CRT) as options…